Use of antiplatelet agents in patients with chronic kidney disease: What is the evidence?;Antiagrégants plaquettaires chez les patients avec insuffisance rénale chronique: Quelles sont les évidences concernant leur utilisation?

Revue Medicale Suisse

Volumn 10, Issue 419, 2014, Pages 487-492

  Gabrielli, A ^a   Bouatou, Y ^b   Saudan, P ^b  

^a SERVICE DE MÉDECINE INTERNE GÉNÉRALE   (Switzerland)

^b Service de Nephrologie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT;

BLEEDING; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; HUMAN; REVIEW; RISK FACTOR; THROMBOSIS;

ADENOSINE; BLOOD PLATELET DISORDERS; EVIDENCE-BASED PRACTICE; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; RENAL INSUFFICIENCY, CHRONIC; THIOPHENES; THROMBOSIS; TICLOPIDINE;

EID: 84895421640     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Eckardt KU, Coresh J, Devuyst O, et al. Evolving importance of kidney disease: From subspecialty to global health burden. Lancet 2013;382:158-69.
2. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47. (Pubitemid 350074801)
3. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 2010;375:2073-81.
4. Morel O, Muller C, Jesel L, Moulin B, Hannedouche T. Impaired platelet P2Y12 inhibition by thienopyridines in chronic kidney disease: Mechanisms, clinical relevance and pharmacological options. Nephrology, dialysis, transplantation: Official publication of the European Dialysis and Transplant Association - European Renal Association 2013;28:1994-2002.
5. Jain N, Hedayati SS, Sarode R, Banerjee S, Reilly RF. Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: What is the evidence? Clin J Am Soc Nephrol 2013;8:665-74.
6. *Basra SS, Tsai P, Lakkis NM. Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. J Am Coll Cardiol 2011;58:2263-9.
7. Gremmel T, Muller M, Steiner S, et al. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. Nephrol Dial Transplant 2013;28:2116-22.
8. *Palmer SC, Di Micco L, Razavian M, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: A systematic review and meta-analysis. Ann Intern Med 2012;156:445-59.
9. Best PJ, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002;39:1113-9. (Pubitemid 34267412)
10. Gaglia MA, Waksman R. Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor. Circulation 2011;123:451-6.
11. Sartipy U, Rampell E, Carlsson AC, Wandell P, Holzmann MJ. Cardiovascular medication in relation to renal function after coronary artery bypass surgery. Int J Cardiol 2013;168:4033-8.
12. KDIGO. Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD, 2013.
13. Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: A post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol 2010;56:956-65.
14. Floege J, Schlieper G. Chronic kidney disease: How effective and safe are antiplatelet agents in CKD? Nat Rev Nephrol 2013;9:314-6.
15. Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial 2006;19:317-22. (Pubitemid 44091707)
16. Limdi NA, Beasley TM, Baird MF, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009;20:912-21.
17. Sood MM, Larkina M, Thumma JR, et al. Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: Results from the DOPPS. Kidney Int 2013;84:600-8.
18. Holden RM, Harman GJ, Wang M, Holland D, Day AG. Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:105-10.
19. Htun P, Fateh-Moghadam S, Bischofs C, et al. Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J Am Soc Nephrol 2011;22:627-33.
20. Yeung CK, Shen DD, Thummel KE, Himmelfarb J. Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int 2013; epub ahead of print.
21. Best PJ, Steinhubl SR, Berger PB, et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 2008;155:687-93.
22. Fontana P, Cattaneo M, Combescure C, Reny JL. Tailored Thienopyridine therapy: No urgency for CYP2C19 genotyping. J Am Heart Assoc 2013;2:e000131.
23. Pellaton C, Eeckhout E, Silvain J, Montalescot G, Collet JP. Tests de réactivité plaquettaire: mise à jour pour le praticien. Rev Med Suisse 2013;10:412-3.
24. Small DS, Wrishko RE, Ernest CS, et al. Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease. J Clin Pharm Ther 2009;34:585-94.
25. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
26. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: Results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2010;122:1056-67.